Prevymis (letermovir) - Merck (MSD)
Livtencity (maribavir) - Takeda, GSK
Human Cytomegalovirus Virion-Associated mRNA as a Marker of Productive Infection in Immunocompromised Patients. (PubMed, J Med Virol) - May 6, 2025 - "Moreover, UL21.5 mRNA was positive in patients who developed HCMV infection resistant to letermovir or maribavir, whereas it was undetectable in the plasma of patients with transient self-resolving DNAemia blips during letermovir prophylaxis (not associated with drug-resistance). HCMV UL21.5 mRNA in plasma is virion-associated and represents a marker for productive HCMV infection. The determination of UL21.5 mRNA could improve current strategies for the management of HCMV infection in immunocompromised patients." 
Biomarker • Journal • Cytomegalovirus Infection • Infectious Disease • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/40326958
 
Nicola Polverelli; Antonino Maria Guglielmo Pitrolo; Dalila Mele; Daniele Lilleri; Domenica Federica Briganti; Elena Seminari; Eleonora Francesca Pattonieri; Fausto Baldanti; Federica Giardina; Francesca Compagno; Giulia Campanini; Irene Cassaniti; Josè Camilla Sammartino; Marilena Gregorini; Marina Ramus; Omar Mura; Piera d'Angelo; Stefania Paolucci; Teresa Rampino
 
May 6, 2025
 
Prev Next